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Abstract
Background: Few pharmaceuticals are registered in cats for the management of post-operative pain and
inflammation. The objective of this study was to assess the field efficacy and safety of an injectable formulation of
the nonsteroidal anti-inflammatory drug robenacoxib in cats undergoing surgery. The study was a multi-center,
prospective, randomized, masked, parallel-group, placebo-controlled clinical trial. A total of 349 cats were enrolled
and underwent surgery comprising forelimb onychectomy, as an example of orthopedic surgery, plus either
ovariohysterectomy or castration. All cats received butorphanol prior to anesthesia and forelimb four-point regional
nerve blocks with bupivacaine after induction of general anesthesia. Cats were randomized to receive daily
subcutaneous (s.c.) injection of robenacoxib, at a target dosage of 2.0 mg/kg (n = 174), or placebo (n = 175) once
prior to surgery and for an additional two days post-operatively.
Results: Significantly (P = 0.037) fewer cats administered robenacoxib received additional analgesia rescue therapy
(34 of 173, 19.7 %) compared to cats given placebo (73 of 175, 41.7 %). The percentage of treatment success was
therefore 80.3 % with robenacoxib and 58.3 % with placebo. Behavior, posture, pain on palpation of the paw and
soft tissue surgery sites, and overall pain were significantly (P < 0.05) improved versus placebo at various time points
within the first 8 h in cats receiving robenacoxib. The most frequently reported adverse events were incision site
infection/dehiscence, bleeding, vomiting, decreased appetite and lethargy. Frequencies of reported adverse clinical
signs, hematology, serum chemistry and urinalysis variables, and body weight changes were similar between
groups. There were no significant changes from baseline with robenacoxib in hepatic, hematological or renal
clinical pathology variables.
Conclusions: Robenacoxib by s.c. injection was effective and well tolerated in the control of post-operative pain
associated with orthopedic, ovariohysterectomy and castration surgery in cats.
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Background
Pain management has been used increasingly as the stand-
ard of practice in cats undergoing surgery [1, 2]. In addition
to improving animal welfare, control of post-operative pain
and inflammation facilitates the healing process and helps
avoid the development of chronic pain [3].
Opioids and nonsteroidal anti-inflammatory drugs
(NSAID) are the classes of drugs used most frequently
for controlling pain and inflammation in the immediate
post-operative period. However, only few NSAIDs are li-
censed for use in cats, probably due to the relatively
poor safety profile of several NSAIDs in this species [4].
Robenacoxib is a coxib class NSAID that demonstrates
high selectivity for the cyclo-oxygenase-2 enzyme [5].
Robenacoxib injection (2 mg/kg body weight by the sub-
cutaneous (s.c.) route) and tablets (1 mg/kg with a range 1-
2.4 mg/kg) are registered in cats for up to three days use for
the treatment of pain and inflammation associated with
orthopedic or soft tissue surgery in the EU (www.ema.euro-
pa.eu) [6] and for the control of post-operative pain and
inflammation associated with orthopedic surgery, ovario-
hysterectomy and castration in the US (www.fda.gov/
Drugs). Randomized, masked, non-inferiority clinical stud-
ies demonstrated superior efficacy of injectable robenacoxib
in reducing post-operative pain compared to meloxicam in
a Japanese study [7] and non-inferior efficacy in an EU
study [8]. Superior efficacy of oral robenacoxib in reducing
post-operative pain compared to placebo was reported in a
previous US field study [9].
The objective of the present US study was to demon-
strate the field effectiveness and safety of injectable
robenacoxib at a dose of 2.0 mg/kg for the control of
post-operative pain associated with onychectomy, ovar-
iohysterectomy and castration surgery in cats.
Methods
Study design
The study was a multi-center, randomized, masked,
placebo-controlled, parallel-group clinical trial at 13
companion animal veterinary clinics located at various
geographic locations within the US.
The study was conducted in accordance with guide-
lines for Good Clinical Practice (VICH GL9), Adequate
and Well-controlled Studies (21 CFR 514.117) and New
Animal Drugs for Investigational Use (21 CFR 511.1)
(www.fda.gov/AnimalVeterinary/GuidanceComplian-
ceEnforcement/). The protocol was reviewed and ap-
proved by the Food and Drug Administration (FDA) and
Novartis Animal Health Institutional Animal Care and
Use Committee. All owners provided written consent at
the pre-enrollment visit (Day -14 to -2) for their cat to
enter the study.
This manuscript was prepared in compliance with the
CONSORT guidelines on randomized trials [10].
Selection criteria
Clinically normal intact cats that were ≥4 months of age
and weighing between 2.5 and 12 kg (inclusive) at the
time of enrollment and presented to the clinic for ovar-
iohysterectomy or castration plus forelimb onychectomy
(declaw) were included.
Exclusion criteria were cats meeting any of the follow-
ing criteria:
 pregnant;
 uncontrolled endocrine or systemic disorders
(diabetes mellitus or hyperthyroidism had to be
stabilized for at least 28 days prior to inclusion);
 history of concurrent diseases involving coagulation
or circulatory or integumentary systems, distal
limbs, gastrointestinal tract, kidney or liver;
 surgical intervention within 2 weeks of screening;
 requiring additional procedures that might interfere
with assessments of pain;
 treated with alternative forms of pain relief (e.g.,
chiropractic manipulation, dry or wet acupuncture,
acupressure, clinical therapy) within 30 days, a
topical or systemic anti-inflammatory product such
as an NSAID within 14 days, a short-acting (sys-
temic or local) corticosteroid within 30 days, or
long-acting corticosteroids within 60 days before in-
clusion into the study;
 known intolerance to any of the anesthetics used
during the study; and
 known to be fractious, aggressive or frightened in a
veterinary practice
Anesthesia and analgesia protocol
With the exception of xylazine and medetomidine
(which have analgesic properties), any combination of
available products to facilitate induction, maintenance
and recovery from anesthesia was allowed. All cats were
adequately hydrated prior to and during surgery.
To provide a minimum level of pain control, all cats
received butorphanol at a dose of 0.4 mg/kg body weight
s.c. as an anesthetic pre-medication, followed by a meta-
carpal four-point ring block with bupivacaine (0.5 %)
under aseptic conditions to provide local anesthesia [11].
The total dose of bupivacaine for both paws did not ex-
ceed 5.0 mg per kg body weight. The following nerves
were blocked: median nerve, palmar branches of the
ulnar nerve, dorsal digital nerves II to V and dorsal
digital nerve I [9].
Randomization and treatment
Cats selected for the study were formally included on
Day 0 and randomly allocated to one of the treatment
groups in a 1:1 ratio in blocks of four. Cats were admin-
istered either the injectable form of robenacoxib s.c. at a
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dosage of 2 mg/kg of body weight (Onsior®, Elanco
Animal Health, Greenfield, US) or 0.1 mL/kg placebo
(0.9 % sodium chloride injection, USP) once daily for
3 days. The dosage of 2 mg/kg was determined from a
laboratory kaolin model study [12] and was confirmed in
field studies in Japan and the EU [7, 8]. The dose admin-
istered to each cat was calculated from the pre-
anesthetic body weight determined on Day 0. The first
treatment was given approximately 30 min prior to sur-
gery or at the same time the pre-anesthetic agents were
administered. Subsequent once daily injections were
given at approximately the same time each day.
The randomization list was computer-generated by the
statistician. Masking was maintained as robenacoxib for
injection was similar in appearance to the placebo. In
addition, a treatment administrator (i.e. dispenser) at
each clinic was responsible for dispensation and recon-
ciliation of used and unused products. All study site
personnel were masked to treatment assignment except
the dispenser.
Clinical examinations and follow-up
Clinical examinations were performed prior to enroll-
ment and on Day 0 (prior to surgery) and Day 2 (study
exit), in cases of early withdrawal, and for any animal
which experienced a serious adverse event (SAE). The
examination included a routine assessment of general
appearance, body weight and major systems.
Premature completion and follow-up
Cats could be withdrawn from the study and/or receive
rescue analgesic therapy at any time at the discretion of
the veterinarian. Cats receiving rescue intervention were
observed in the clinic for a minimum of 24 h post-
intervention and any potential adverse events (AEs) were
documented. The owners of study cats received a
follow-up phone call approximately 3 to 7 days after
normal or premature completion to assess the animal’s
general well-being.
Rescue therapy and prohibited concomitant medications
If at any time the veterinarian determined a cat to be
uncomfortable or in pain, the cat received additional
butorphanol tartrate or any other product selected by
the investigator (except other NSAIDs) to control pain
as rescue analgesic therapy.
The following treatments were not allowed during the
study: additional analgesic drugs or NSAIDs, synthetic fe-
line facial pheromone (i.e., FELIWAY® Pheromone Spray),
corticosteroids, α2-adrenoceptor agonists (e.g., medetomi-
dine or xylazine) or alternative forms of pain relief (e.g.,
acupressure, dry or wet acupuncture, chiropractic manipu-
lation, clinical therapy).
Surgical procedures
Cats underwent onychectomy in addition to either castra-
tion or ovariohysterectomy. Onychectomy (declaw) was
performed on the cats’ forelimbs (only) using one of the
following procedures: guillotine nail trimmer, laser or surgi-
cal scalpel. Ovariohysterectomy was performed through a
standard ventral midline incision. A flank approach, which
was associated with higher wound pain in one study, was
not allowed [13]. Castrations were performed through the
standard scrotal approach. Cryptorchid cats were eligible
and the surgical site was evaluated accordingly.
Efficacy assessments
All efficacy assessments for each cat were made by the
same veterinarian. The primary efficacy variable was the
need for rescue therapy, decided by the veterinarian, to
control post-operative pain (treatment failure) in the cats.
Secondary efficacy variables included the assessment
of posture, behavior (viewed from a distance and deter-
mined following social interaction), pain elicited on pal-
pation (paws and soft tissue incision site) and overall
pain control (Appendix). A baseline evaluation of the
secondary variables was performed on Day 0 after the
cat had acclimatized for a minimum of 2 h in the clinic,
and prior to administration of the test items or pre-
anesthetic agents.
The evaluations for the primary and secondary vari-
ables were conducted at the time of post-surgical extu-
bation (defined as 0 min) and thereafter at 30 min
(±10 min); 1 h (±10 min); 3, 5 and 8 h (±15 min); 24, 28,
32, 48 and 52 h (±1 h).
Safety assessments
Safety was assessed, in all cats which had received at
least one dose of injectable robenacoxib or placebo, from
all reported AEs, injection site reactions (warmth, visible
swelling, palpation), post-study owner follow-up,
changes in body weight and clinical pathology variables
(hematology, serum chemistry and urinalysis).
Statistical analysis
The study was planned to include a minimum of 300
cats, with 150 cats in each of the robenacoxib and pla-
cebo groups. All analyses were performed using SAS/
STAT® software [14]. Unless stated otherwise, data are
presented as mean (SD). Statistical significance was con-
cluded with two-tailed P values less than 0.05. The ex-
perimental unit was each individual cat.
Primary efficacy variable
The primary efficacy variable was the frequency of res-
cue therapy (“rescue” or “treatment failure”), with super-
iority established by a statistically significant lower
proportion of rescues in the robenacoxib group
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compared to the placebo group. A general linear model
(PROC GLIMMIX) was used with fixed effect of ‘treat-
ment’ and the random effects of ‘site’ and ‘treatment by
site’. A logit link function was used because the analysis
involved the binary variable ‘outcome’ (i.e., ‘success’ or
‘failure’). In addition, the ‘time to rescue’ for each cat
was assessed from a Kaplan-Meier survival curve with
comparison of groups using the log-rank, Cox-Tarone
and Gehan-Breslow tests.
Secondary efficacy variables
The secondary efficacy variables (posture, behavior, pain
elicited on palpation and overall pain control) were categor-
ical and were measured multiple times during the study.
Data on the day of surgery (extubation to 8 h) were com-
pared statistically using PROC GLIMMIX. The model in-
cluded the fixed effects of ‘treatment’, ‘time’ and ‘treatment
by time’, the random effects of ‘site’, ‘treatment by site’ and
‘treatment by site and time’. The Last Observation Carried
Forward (LOCF) method [15] was used up to 8 h post-
extubation in order to take into account results from cats
that received rescue therapy on the day of surgery. After
8 h, the LOCF method was not used, and results were not
compared statistically, as the data became less meaningful
due to (unequal) withdrawal of cases from the study.
Hematology, serum chemistry and urinalysis variables
were evaluated statistically using analysis of covariance
(ANCOVA; PROC MIXED) with the pre-treatment value
as covariate. The model included the fixed effect of
‘treatment’ and random effects of ‘site’ and ‘treatment by
site’. Levene’s test for homogeneity of variance was per-
formed prior to ANCOVA. If the results from the
Levene’s test were not significant (P > 0.01), untrans-
formed data were used in the ANCOVA, and if signifi-
cant (P ≤ 0.01) logarithmic, square root or reciprocal
transformations were made.
The change in body weight from Day 0 to the end of
the study (or exit) was analyzed using analysis of vari-
ance (ANOVA; PROC MIXED), with the fixed effects of




A total of 349 cats were enrolled in the study and all
were included in the demographic and safety analysis,
including reports of AEs: 174 cats received robenacoxib
and 175 received placebo.
The cats were aged 4 months to 9 years and weighed 2.4
to 6.0 kg at enrollment (Day 0). Most cats (73.4 %) were
aged ≤1 year and were in the weight range 2.5–3.4 kg
(64.8 %). The most common breed was domestic short
hair (74.8 % of cats) (Table 1). Similar numbers of males
and females were enrolled within the groups; the
percentages of cats undergoing ovariohysterectomy (52.3
and 54.9 %) and castration (47.7 and 45.1 %) were similar
in the robenacoxib and the placebo groups, respectively.
Of the 349 cats enrolled in the study, 348 were ana-
lyzed for efficacy variables. One cat, which received
robenacoxib, was not included because the animal died
prior to surgery due to anesthetic equipment malfunc-
tion that was judged to be unrelated to the administra-
tion of robenacoxib.
Primary efficacy variable
During the study, a total of 107 cats received rescue an-
algesic therapy with 34 of 173 cases (19.7 %) in the robe-
nacoxib group compared to 73 of 175 cases (41.7 %) in
the placebo group. The percentage of treatment success
was therefore 80.3 % with robenacoxib and 58.3 % with
placebo. Using Proc GLIMMIX, the difference between
groups was statistically significant (P = 0.0370), with least
squares mean estimates of 83.5 and 61.9 % treatment
success for robenacoxib and placebo groups respectively.
The majority of rescues occurred at or before 8 h
post-extubation, with 56/107 (52 %) at ≤ 3 h, 77/107
(72 %) at ≤ 5 h and 91/107 (85 %) at ≤ 8 h. The number
of cats receiving rescue therapy at the 0, 0.5, 1, 3, 5, 8,
24 and 28 h time points (or in the interval since the pre-
vious time point) was respectively 0, 4, 6, 7, 4, 5, 7 and 1
in the robenacoxib group (total 34) and 0, 6, 11, 22, 17,
9, 6 and 2 in the placebo group (total 73).
In the robenacoxib group, the proportion of cats rescued
was similar for guillotine-type nail trimmer (32.4 %), laser
scalpel (32.4 %) and surgical (35.3 %) methods (Table 2). In
the placebo group, however, more cats were rescued when
onychectomy was performed by the guillotine-type nail
Table 1 Demographic data of the cats
Variable Robenacoxib (n = 174) Placebo (n = 175)
N % N %
Gender
Female 91 52.3 96 54.9
Male 83 47.7 79 45.1
Breed
Domestic short hair 133 76.4 128 73.1
Domestic medium hair 10 5.7 14 8.0
Domestic long hair 16 9.2 18 10.3
Himalayan 2 1.1 0 0.0
Manx 0 0.0 1 0.6
Persian 2 1.1 0 0.0
Ragdoll 3 1.7 2 1.1
Selkirk rex 0 0.0 1 0.6
Siamese 7 4.0 8 4.6
Siamese mix 1 0.6 3 1.7
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trimmer (41.1 %) compared to the laser scalpel (28.8 %)
and surgical (30.1 %) methods.
In the survival analysis, the log-rank, Cox-Tarone and
Gehan-Breslow tests were all highly significant (P < 0.0001)
in favor of the robenacoxib group. The robenacoxib
group had a lower probability of failures (rescue) at
30 min post-extubation and all subsequent remaining
times compared to the placebo group (Fig. 1).
The most common reasons for administering rescue
therapy were tenderness of surgical sites, agitation, ag-
gressive or defensive/guarding behavior, hunched pos-
ture and vocalization (Table 3).
Secondary efficacy variables
For the individual variables, the analysis showed statisti-
cally significant (P < 0.05) differences between groups and
in favor of robenacoxib for behavior (from a distance and
following social interaction), soft tissue incision site pain
on palpation and overall pain score at assessment times 1,
3, 5 and 8 h; and posture and paw pain on palpation
scores at 3, 5 and 8 h (Table 4).
Safety – adverse events
Adverse events and post-study phone findings were re-
ported in 26 of 174 cases (14.9 %) in the robenacoxib
group and 9 of 175 cases (5.1 %) in the placebo group.
Table 5 provides a summary of the number and percent-
age of cases with each reported AE.
The most common AEs reported in cats treated with
robenacoxib were incision site infection/dehiscence,
increased incision site bleeding, vomiting, decreased ap-
petite and lethargy. In the placebo group the most com-
mon AEs reported were increased incision site bleeding
and decreased appetite.
During the study, one cat in the robenacoxib treat-
ment group died due to cardiopulmonary failure prior to
surgery as a result of an anesthesia equipment malfunc-
tion that caused pneumothorax. The cat was excluded
from the efficacy and clinical pathological analyses. One
death (placebo group) was reported following the com-
pletion of the study; the cat died from an obstructed ur-
ethra resulting in kidney failure and presumed heart
failure due to elevated potassium concentrations.
Safety - clinical pathology
Selected kidney, liver and hematology variables at the
study exit are shown in Table 6.
Mean values for all serum chemistry variables in both
treatment groups were within normal reference ranges
with the exception that creatine phosphokinase at study
exit in both the robenacoxib (1468.0 U/L) and placebo
(1151.8 U/L) groups was higher than the upper limit
(529 U/L) of the normal range.
The blood urea nitrogen to creatinine ratio, chloride
and triglyceride values were significantly higher at study
exit in the robenacoxib compared to the placebo group
(P = 0.016, 0.032, and 0.018, respectively). The glucose
values were significantly lower in the robenacoxib com-
pared to the placebo group (P = 0.0086).
Mean values for all hematology variables at pre-
treatment and study exit were within the normal refer-
ence range in both groups with the exception of the
Table 2 Number of cats that received rescue analgesia
according to surgical methods
Surgery/group Surgery type N % of total
Onychectomy
Robenacoxib Guillotine-type nail trimmer 11 32.4 %
Laser scalpel 11 32.4 %
Surgical 12 35.3 %
Total 34
Placebo Guillotine-type nail trimmer 30 41.1 %
Laser scalpel 21 28.8 %
Surgical 22 30.1 %
Total 73
Soft tissue surgery
Robenacoxib Castration 11 32.35 %
Ovariohysterectomy 23 67.65 %
Total 34
Placebo Castration 31 42.5 %
Ovariohysterectomya 42 57.5 %
Total 73
aIncludes three female cats that were found to have already been neutered
i.e. they underwent abdominal exploratory surgery
Time (hours)





























Fig. 1 Kaplan-Meier plot of time to rescue analgesia therapy. The data
show the percentage of cats at each time point which had not received
rescue therapy to control post-operative pain (defined as treatment
failure). Time 0 was fixed as the time of post-surgical extubation. There
was a lower frequency of treatment failure in the robenacoxib group
compared to the placebo at 30 min and all subsequent times. P< 0.0001
with log-rank, Cox-Tarone and Gehan-Breslow tests
King et al. BMC Veterinary Research  (2016) 12:215 Page 5 of 10
absolute neutrophil counts at study exit (8589.4 cells/
μL) for the placebo group, which were slightly higher
than the upper limit (8500 cells/μL) of the normal range.
The percentage of lymphocytes was significantly higher
in the robenacoxib compared to the placebo group (P =
0.031); however, the difference in the absolute lympho-
cyte counts was not statistically significant (P = 0.078).
Safety - body weight
There was no significant (P = 0.11) difference in change
from baseline in body weight between the robenacoxib
and placebo groups (−0.027 [0.13] and −0.05 [0.13] kg,
respectively).
Safety - injection site reaction
One cat in the robenacoxib group had a mild swelling at
the Day 2 injection site, which was observed at study
exit. Another cat in the robenacoxib group had “greasy
hair” at the Day 2 injection site that was observed at
study exit. A further cat in the placebo group had “blood
around injection site” for the Day 0 injection site that
was observed on Day 2.
Discussion
In this clinical trial of cats undergoing forelimb ony-
chectomy in combination with ovariohysterectomy or
castration, all animals received pre-surgical analgesia
with butorphanol and a regional nerve block.
Addition of robenacoxib by s.c. injection, approxi-
mately 30 min prior to surgery and then once daily
for two subsequent days, was well tolerated and
provided better control of post-operative pain com-
pared to placebo. The superior efficacy of robenacoxib
compared to placebo was evidenced from the signifi-
cantly (P = 0.037) lower frequency of rescue therapy
(19.7 % versus 41.7 %, the primary endpoint), which
is consistent with a treatment success rate of 80.3 %
versus 58.3 %. In addition, robenacoxib demonstrated
superior efficacy to the placebo for the secondary
endpoints of posture, behavior assessed from a dis-
tance and during social interaction, as well as pain
assessed at the paw, soft tissue incision site and over-
all. Similar results were obtained previously with
robenacoxib tablets [9], and in both studies once daily
dosing with robenacoxib by injection or tablets pro-
vided effective analgesia over the 24 h dosing interval.
These results support previous findings that robena-
coxib has a longer duration of action than would be
predicted from its short blood half-life, explained by
concentration and persistence at sites of inflammation
[16, 17]. The endpoints included in this study did not
include specific measures of inflammation. Inhibition
of inflammation, pain and fever by robenacoxib was
demonstrated previously in an experimental kaolin
model in cats [12].
Onychectomy is a model of orthopedic surgery and
has been used in several studies for testing analgesics
and NSAIDs in cats, either alone or in combination with
neutering [11, 18–21]. In this study, therefore, cats
underwent both orthopedic (onychectomy) and soft tis-
sue (ovariohysterectomy or castration) surgeries. The
frequency of rescue analgesia was 19.7 % with
Table 3 Reasons for rescue analgesic therapy
Reason Robenacoxib Placebo
N % of total (n = 34) N % of total (n = 73)
Tenderness of surgical sites 23 67.7 % 60 82.2 %
Agitated 21 61.8 % 46 63.0 %
Aggression or defensive/guarding behavior 21 61.8 % 38 52.1 %
Hunched posture 19 55.9 % 38 52.1 %
Vocalized response 18 52.9 % 36 49.3 %
Purposeful avoidance of painful stimulus 16 47.1 % 35 48.0 %
Chewing, licking, or biting of surgical sites 15 44.1 % 27 37.0 %
Little or no social response 12 35.3 % 13 17.8 %
Dilated pupils 10 29.4 % 14 19.2 %
Trembling or shaking 9 26.5 % 25 34.3 %
Tachycardia or tachypnea 8 23.5 % 10 13.7 %
Poor or unkempt appearance 5 14.7 % 1 1.4 %
Difficult or violent post anesthetic recovery 4 11.8 % 8 11.0 %
Othera 3 8.8 % 1 1.4 %
More than one reason may have been reported for each cat
a “Other” included clinical signs that the investigator associated with pain, including licking lips, holding ears down/flat when palpated, breathing hard and not
allowing an assessment of the paws
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Table 4 Summary statistics for secondary efficacy variables




Paw pain on palpation
score




Mean (SD) P value Mean (SD) P value Mean (SD) P value Mean (SD) P value Mean (SD) P value Mean (SD) P value
Robenacoxib 0 175 3.72 (0.83) 0.85 1.18 (0.51) 0.95 1.99 (1.19) 0.78 4.82 (0.49) 0.72 1.06 (0.27) 0.51 1.11 (0.35) 0.75
Placebo 173 3.70 (0.89) 1.17 (0.51) 1.97 (1.21) 4.86 (0.41) 1.02 (0.15) 1.09 (0.32)
Robenacoxib 30 min 175 3.06 (1.06) 0.54 1.31 (0.55) 0.19 1.92 (1.04) 0.26 4.39 (0.96) 0.12 1.24 (0.55) 0.60 1.36 (0.56) 0.12
Placebo 173 2.99 (1.12) 1.23 (0.49) 1.80 (0.93) 4.56 (0.68) 1.21 (0.43) 1.25 (0.50
Robenacoxib 1 h 175 2.65 (1.16) 0.24 1.35 (0.56) 0.049 1.88 (0.95) 0.042 4.19 (1.08) 0.052 1.37 (0.59) 0.0067 1.50 (0.65) 0.0050
Placebo 173 2.52 (1.18) 1.24 (0.49) 1.67 (0.89) 4.40 (0.93) 1.20 (0.47) 1.31 (0.59)
Robenacoxib 3 h 175 2.32 (1.15) 0.0022 1.43 (0.61) 0.0086 1.81 (0.92) 0.0079 3.73 (1.27) <0.0001 1.53 (0.73) 0.0001 1.66 (0.75) <0.0001
Placebo 173 1.98 (1.07 1.27 (0.53) 1.53 (0.84) 4.22 (0.96) 1.30 (0.52) 1.37 (0.65)
Robenacoxib 5 h 175 2.21 (1.07) 0.0001 1.49 (0.66) 0.0001 1.83 (0.94) 0.0011 3.57 (1.37) <0.0001 1.60 (0.76) 0.0076 1.78 (0.82) <0.0001
Placebo 173 1.78 (0.93) 1.26 (0.53) 1.50 (0.81) 4.02 (1.02) 1.44 (0.57) 1.43 (0.68)
Robenacoxib 8 h 175 2.10 (1.07) 0.0001 1.50 (0.68) <0.0001 1.81 (0.93) 0.0006 3.52 (1.33) 0.0008 1.65 (0.75) 0.0017 1.83 (0.82) <0.0001
Placebo 173 1.66 (0.87) 1.20 (0.51) 1.45 (0.77) 3.88 (1.06) 1.46 (0.60) 1.43 (0.67)
Robenacoxib 24 h 107 1.32 (0.61) ND 1.07 (0.25) ND 1.21 (0.49) ND 4.11 (1.0) ND 1.34 (0.58) ND 1.18 (0.45) ND
Placebo 146 1.36 (0.60) 1.05 (0.23) 1.25 (0.59) 3.99 (1.05) 1.39 (0.59) 1.22 (0.51)
Robenacoxib 28 h 104 1.36 (0.67) ND 1.04 (0.19) ND 1.13 (0.39) ND 4.16 (0.92) ND 1.33 (0.57) ND 1.16 (0.37) ND
Placebo 140 1.26 0.54 1.04 (0.19) 1.19 (0.46) 3.99 (0.92) 1.37 (0.55) 1.16 (0.39)
Robenacoxib 32 h 102 1.30 (0.63) ND 1.02 (0.14) ND 1.13 (0.36) ND 4.14 (1.02) ND 1.30 (0.56) ND 1.13 (0.34) ND
Placebo 139 1.24 (0.49) 1.02 (0.15) 1.17 (0.45) 4.01 (0.93) 1.37 (0.56) 1.17 (0.37)
Robenacoxib 48 h 102 1.23 (0.51) ND 1.01 (0.10) ND 1.10 (0.33) ND 4.06 (0.98) ND 1.26 (0.56) ND 1.12 (0.32) ND
Placebo 139 1.15 (0.38) 1.01 (0.12) 1.09 (0.36) 3.96 (0.95) 1.28 (0.50) 1.07 (0.26)
Robenacoxib 52 h 102 1.20 (0.47) ND 1.01 (0.10) ND 1.11 (0.34) ND 4.11 (0.92) ND 1.28 (0.55) ND 1.10 (0.30) ND
Placebo 139 1.12 (0.35) 1.02 (0.15) 1.09 (0.36) 4.07 (0.94) 1.27 (0.52) 1.06 (0.24)
P values less than 0.05 are shown in bold. Statistical analyses were performed only on data from time 0 min through hour 8













robenacoxib and 41.7 % with placebo, used in addition
to pre-surgery butorphanol and bupivacaine nerve
blocks. A previous study using an identical methodology
reported similar results with robenacoxib tablets
(16.5 %) compared to placebo (46.3 %) [9]. Other histor-
ical studies in cats undergoing onychectomy with or
without neutering reported the following frequencies of
rescue therapy: 95 % (negative control) and 17 % (pre
and post-surgery butorphanol) [11]; 67 and 71 % with
single pre-surgery meloxicam and butorphanol, respect-
ively [20]; and 27 % (transdermal fentanyl patch) and
9 % (butorphanol) [18]. In none of these studies did cats
receive pre-surgery local anesthesia, although one study
did not show any additional analgesic benefit of a four-
point regional nerve block with bupivacaine, when added
to buprenorphine [21]. In a fourth study, no rescue
therapy was administered to cats undergoing only
onychectomy after receiving butorphanol or transdermal
fentanyl [19].
This study was a comparison of injectable robenacoxib
to a placebo. Administration of placebo to animals in
pain studies raises ethical and welfare issues; however,
these were overcome by providing both butorphanol and
regional bupivacaine nerve blocks to all cats prior to sur-
gery. The efficacy of butorphanol has been demonstrated
compared to a negative control in cats undergoing ony-
chectomy, with or without neutering, at an intramuscu-
lar dosage of 0.2 mg/kg, lower than the 0.4 mg/kg
dosage used in this study [11]. Local nerve block with
bupivacaine has also been tested in cats undergoing ony-
chectomy; however, no significant benefit when added to
buprenorphine was reported in one study [21]. A
185 min duration of action was reported for intramuscu-
lar administration of 0.4 mg/kg butorphanol using the
thermal threshold method in healthy cats [22]. The re-
sults from this study suggest that butorphanol and bupi-
vacaine did not have strong efficacy, however, since






N % of total N % of total
Incision site infection, dehiscence 9 5.2 0 0
Increased incision site bleeding 6 3.4 4 2.3
Vomiting 5 2.9 0 0
Decreased appetite 4 2.3 3 1.7
Lethargy (after day of surgery) 4 2.3 2 1.1
Urinary tract infection 2 1.1 0 0
Coughing 1 0.6 0 0
Fever 1 0.6 0 0
Semiconsciousb 1 0.6 0 0
Soft stool or diarrhea 0 0 2 1.1
Cats may have experienced more than one type or occurrences of an event
aNot including one cat treated with robenacoxib which suffered
cardiopulmonary failure after a pneumothorax was caused by failure of the
non-rebreathing equipment shortly after intubation
bSemiconscious cat full recovered
Table 6 Selected kidney, liver and hematological variables at study exit
Variable
(Laboratory reference range)
Robenacoxib (n = 170) Placebo (n = 172) P value
Mean (SD) Na Mean (SD) Na
Higher Lower Higher Lower
Serum
Urea nitrogen, mg/dL (14–36 mg/dL) 23.5 (6.58) 6 2 22.1 (5.82) 3 2 0.21
Creatinine, mg/dL (0.6–2.4 mg/dL) 0.88 (0.19) 0 2 0.94 (0.32) 1 6 0.093
Alkaline phosphatase, U/L (6–102 U/L) 48.5 (25.8) 5 0 52.5 (31.3) 14 0 0.10
Alanine aminotransferase, U/L (10–100 U/L) 52.1 (19.1) 5 4 58.6 (44.7) 8 3 0.26
Aspartate aminotransferase, U/L (10–100 U/L) 32.7 (21.7) 3 0 31.3 (18.1) 3 0 0.59
Total bilirubin, mg/dL (0.1–0.4 mg/dL) 0.11 (0.031) 0 0 0.11 (0.043) 1 0 0.54
Total protein, g/dL (5.2–8.8 g/dL) 6.91 (0.63) 1 0 6.95 (0.55) 0 0 0.34
Albumin, g/dL (2.5–3.9 g/dL) 3.44 (0.36) 11 1 3.44 (0.34) 8 1 0.47
Hematology
Hemoglobin, g/dL (9.3–15.9 g/dL) 12.1 (1.57) 1 5 11.9 (1.74) 0 10 0.49
Hematocrit, % (29–48 %) 37.0 (5.19) 6 8 36.4 (5.57) 1 18 0.39
Platelet count, 103/μL (200–500 103/μL) 275.4 (105.0) 5 39 290.8 (109.5) 6 31 0.51
Urineb
Urine specific gravity (1.015–1.060) 1.067 (0.018) 109 0 1.058 (0.019) 79 6 0.014
P value less than 0.05 is shown in bold
aNumber of cats with value for respective variable higher or lower than the reference range at study exit
bFor urine, n = 160 for both robenacoxib and placebo
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rescue therapy was administered in most cases at early
time points. Of the 107 cats which received rescue anal-
gesia, 56 (52)%, 77 (72 %) and 91 (85 %) were rescued
on or before 3, 5 or 8 h, respectively. In order to
minimize suffering, any cat could be withdrawn from
the study and administered rescue analgesia at any time
at the discretion of the veterinarian.
The most frequently reported AEs were incision site
infection/dehiscence, increased incision site bleeding,
vomiting, decreased appetite and lethargy. Other stud-
ies have reported that 50 % of onychectomy surgeries
have complications including pain, bleeding and lame-
ness, regardless of onychectomy technique [23, 24].
The frequency of incision site infection/dehiscence and
vomiting was higher in the robenacoxib than the pla-
cebo group. Similar findings were reported previously
with robenacoxib tablets in cats undergoing the same
surgeries [9]. It is not known if these results are reli-
able, however, as vomiting was not observed in safety
studies with robenacoxib, even with repeated adminis-
tration of high doses [16], and the impact of NSAIDs
on wound healing in humans was concluded not be
clinically relevant [25].
There was no evidence from this study of any tox-
icity of robenacoxib to target organs that are most
sensitive to NSAID toxicity (gastrointestinal tract, kid-
ney and liver), consistent with previous studies in cats
[16, 26]. At daily dosages up to 20 mg/kg for 42 days,
oral robenacoxib was well tolerated and had no de-
tectable effect on clinical chemistry, coagulation or
hematology variables in healthy young cats [16]. In a
field study in cats with osteoarthritis, robenacoxib tab-
lets at a dose of 1–2.4 mg/kg once daily for one
month were well tolerated with no evidence of gastro-
intestinal, kidney or liver toxicity [26].
The main limitations of this study are discussed
below. First, no specific criteria were pre-defined for
the use of rescue analgesia therapy; the veterinarians
could rescue cats at any time they thought additional
analgesics were necessary. The stated reasons for
administering rescue therapy were in all cases consist-
ent with pain (Table 3), however, and were most
frequently reported as tenderness of surgical sites,
agitation, aggressive or defensive/guarding behavior,
hunched posture and vocalization.
Second, analysis of the secondary efficacy endpoints
was challenging due to the unequal frequency of with-
drawal of cases after administration of rescue therapy
between the two groups with the placebo group having
more rescues than those cats treated with robenacoxib.
The secondary efficacy data for the first 8 h were there-
fore analyzed using the LOCF method. The LOCF
method [15] has limitations, but was justified in this
study since it was used only for cases proactively
withdrawn due to lack of efficacy and for a limited
period (up to 8 h post-extubation).
Conclusions
Robenacoxib by s.c. injection at a target dose of
2.0 mg/kg once daily for three days was effective and
well tolerated in the control of post-operative pain in
cats undergoing orthopedic plus ovariohysterectomy
or castration surgeries.
Appendix





Posture Cat’s overall mobility within
the cage (standing or resting
position), any preferential or
unequal weight distribution
of the limbs, hunched or
retracted posture, position






Behavior Cat’s overall comfort, response
to social interaction with
examiner and / or hospital staff,
level of aggression, level of
vocalization, and ease of
handling as viewed from a















Cat’s level of response to a
gradual increase in pressure
applied to areas adjacent
to the surgical sites. The
response was the amount of
pressure that elicited any level
of pain response from the






























Palpometer® is a device strapped to the index finger which measures pressure
applied to a given area (Palpometer®, University of Victoria Innovation and
Development Corp., PO Box 3075 STN CSC, R Hut McKenzie Avenue, Victoria, BC,
Canada, V8W 3 W2). Scores of 1, 2, 3, 4 and 5 beeps correspond respectively to
pressures of 200, 300, 450, 600 and 800 gf/cm2
All devices were calibrated before use
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